MedPath

Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Phase 3
Completed
Conditions
Dyspepsia
Registration Number
NCT00112203
Lead Sponsor
Forest Laboratories
Brief Summary

Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. Patients feel full after eating; they have bloating and have stomach pain. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia on a long-term basis.

Detailed Description

All patients who have completed study ITOFD04-03 will be offered to continue to be treated with itopride for a period of up to one year in duration. A target of 300 patients will be followed up for 6 months. Of these, a target of 100 patients will be kept on treatment for an additional 6 months.

Patients will need to come to the clinic for evaluations every 8 weeks during the trial. Evaluations done at these visits will include: lab tests, evaluation of the heartburn condition, and a questionnaire needed to be completed by the patient to see if the drug is helpful in relieving their symptoms.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
466
Inclusion Criteria
  • Patients must have completed the 8 week double-blind study ITOFD04-03
  • Female patients must not be pregnant (must have a negative serum pregnancy test)
Exclusion Criteria
  • Patients with any newly occurring medical condition which was an exclusion criterion at ITOFD04-03 study entry

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Long-term safetyevery 2 months
Secondary Outcome Measures
NameTimeMethod
Long-term relief of symptomsevery 2 months
© Copyright 2025. All Rights Reserved by MedPath